###### Strengths and limitations of this study

-   This study has been reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses reporting checklist.

-   Analyses have been undertaken respecting potential sources of known statistical heterogeneity.

-   Searches included both published and unpublished sources of literature to reduce the risk of omitting potentially eligible data.

-   There was a paucity of available data to permit meta-analyses of risk factors for pain and functional impairment.

-   The variability in methods of assessing risk and reporting of frequency of risk characteristics limited analyses.

Introduction {#s1}
============

It has been reported that over 30.8 million US adults suffer from osteoarthritis (OA).[@R1] Between 1990 and 2010, the years lived with disability worldwide caused by OA increased from 10.5 million to 17.1 million, an increase of 62.9%.[@R2] Current OA treatment lacks any disease-modifying treatments with a predominance to manage symptoms rather than modify underlying disease.[@R3] The clinical symptoms of OA can be assessed using several questionnaires, the most common of which is the Western Ontario and Mcmaster Universities Osteoarthritis Index (WOMAC).[@R4] Although pain is recognised as an important outcome measure in OA, it is not clear what the optimal assessment tools are in OA and how they relate to other risk factors.

OA has various subtypes and since current therapies cannot prevent OA progression, early detection and stratification of those at risk may enable effective presymptomatic interventions.[@R7] Several methods are used to define, diagnose and measure OA progression, including imaging techniques (eg, plain radiography, CT and MRI). Plain radiography provides high contrast and high-resolution images for cortical and trabecular bone, but not for non-ossified structures (eg, synovial fluid).[@R9] The most recognised radiographic measure classifying OA severity is Kellgren and Lawrence (KL) grading which assesses osteophytes, joint space narrowing (JSN), sclerosis and bone deformity.[@R10] However, it has been argued that MRI may be more suitable for imaging arthritic joints, providing a whole organ image of the joint.[@R12] Whole-organ MRI scoring method (WORMS) is used in MRI for OA assessing damage, providing a detailed analysis of the joint.

Recently, Outcome Measures in Rheumatology-Osteoarthritis Research Society International (OMERACT-OARSI) have published a core domain set for clinical trials in hip and/or knee OA.[@R13] Six domains were assessed as mandatory in the assessment of OA, including pain, physical function, quality of life, patient's global assessment of the target joint and adverse events including mortality and/or joint structure, depending on the intervention tested. However, there remains a need to identify risk factors for pain and structural damage in OA so that potential interventions can be studied in a timely manner. The purpose of this systematic review was therefore to identify risk factors for pain, worsening function and structural damage that can predict knee/hip OA development and progression. By identifying risk factors for OA pain and structural damage, tools for stratifying specific disease groups could be developed in the future.

Methods {#s2}
=======

This systematic review has been reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses reporting guidelines.

Search strategy {#s2-1}
---------------

A systematic search of the literature was undertaken from 1 January 1990 to 1 February 2020 using electronic databases: Medline (Ovid), Embase (Ovid), Medline, Web of Science and CINAHL (EBSCO). An example of the Embase search strategy of included search terms and Boolean operators is presented in [online supplementary file 1](#SP1){ref-type="supplementary-material"}. Unpublished literature databases including Clinicaltrials.gov, the WHO International Registry of Clinical Trials and OpenGrey were also searched.
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Study identification {#s2-2}
--------------------

Studies were eligible for inclusion if they were a full-text article that satisfied all of the following:

1.  One hundred or more participants analysed in the study (to increase power for comparisons).

2.  Convincing definition of OA using American College of Rheumatology criteria,[@R14] based on symptoms of sustained pain and stiffness in the affected joint, radiographic changes including osteophytes, cartilage loss, bone cysts/sclerosis and JSN, with normal inflammatory markers.

3.  Abstract/title that must refer to pain and/or structure in relation to OA as a primary disease.

4.  Knee or hip OA.

5.  Pain and/or function scores.

6.  Joint imaged.

7.  Minimum 6-month follow-up of pain/function outcome measures.

Non-English studies, letters, conference articles and reviews were excluded.

The titles and abstracts were reviewed by one reviewer (SS). The full text for each paper was assessed for eligibility by one reviewer (SS) and double-checked by a second (TOS). Any disagreements were addressed through discussion and adjudicated by a third reviewer (NS or FH). All studies that satisfied the criteria were included in the review.

Quality assessment {#s2-3}
------------------

To assess the risk of bias and the power of the methodology, the Downs & Black (D&B) tool was applied.[@R15] These tools assessed the following aspects of each study: reporting quality, external validity, internal validity-bias, selection bias and power. The modified D&B tool was used. Accordingly, the 27-item randomised controlled trial (RCT) version was used for RCTs while the 18-item non-RCT version was used for non-RCT designs ([online supplementary file 2](#SP1){ref-type="supplementary-material"}). Both 18-item and 27-item tools have been demonstrated to be valid and reliable tools to assess RCT and non-RCT papers.[@R14] Critical appraisal was performed by one reviewer (SS) and verified by a second (KT). Any disagreements were dealt with by discussion and adjudicated through a third reviewer (TOS). In previous literature, D&B score ranges were given corresponding quality: excellent (scored 26--28); good (scored 20--25); fair (scored 15--19); and poor (scored \<14).[@R14] Item 4 on the non-RCT and item 5 from the RCT tool are scored two points; hence, the total scores equate to 19 and 28 points, respectively. The D&B tool was used to exclude poor quality studies with a score 15/28 or lower in RCTs and 10/19 or lower in non-RCTs.

Data extraction {#s2-4}
---------------

Data were extracted including: subject demographic data, study design, pain and function outcome measures, imaging used, OA severity scores, change in pain and function outcomes and change in OA severity scores. After all relevant data had been extracted, authors of these papers were approached to try and attain individual patient data related to baseline and change in pain, function and structural scores for each study. No data were received from authors to inform this analysis.

Outcomes {#s2-5}
--------

The primary outcome was to determine the development of pain and functional impairment for those with knee and hip OA. The secondary outcome was to determine which factors are associated with structural changes in knee and hip OA.

Data analysis {#s2-6}
-------------

All data were assessed for study heterogeneity through scrutiny of the data extraction tables. These identified that there was minimum study-based heterogeneity based on: population, study design and interventions-exposure variabilities for given outcomes. Where there was study heterogeneity, a narrative analysis was undertaken. In this instance, the ORs of all predictor variables were tabulated with a range of OR presented. Where there was sufficient data to pool (two or more studies with data available to analyse) and study homogeneity evident, a pooled meta-analysis was deemed appropriate. As interpreted by the Cochrane Collaboration,[@R16] when I^2^ was 50% or greater representing high-statistical heterogeneity, a random-effect model meta-analysis was undertaken. When I^2^ was less than this figure, a fixed effects model approach was adopted. Continuous outcomes were assessed using mean difference (MD) scores of measures for developing severe OA, whereas dichotomous variables were assessed through OR data. All data were presented with 95% CIs and forest plots.

Due to the presentation of the data, there were minimal data to permit meta-analyses. Where there were insufficient data to pool the analysis (data only available from one study), a narrative analysis was undertaken to assess risk factors for the development of increased pain and functional impairment. Planned subgroup analyses included determine whether there was a difference in risk factors based on: (1) anatomical regions (ie, difference between hip OA and knee OA); (2) geographical region. Analyses were undertaken on STATA V.14.0 (Stata Corp) with forest plots constructed using RevMan Review Manager (RevMan; Computer program; V.5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.)

Patient and public involvement {#s2-7}
------------------------------

The research team acknowledges the assistance of both the OA tech network and Engineering and Physical Sciences Research Council. The authors also acknowledge receiving assistance from a meeting that enabled a consensus to be met on the eligibility criteria to be used, and this meeting consisted of the following people: Angela Kedgley, Abiola Harrison, Alan Boyde, Alan Silman, Amara Ezeonyeji, Caroline Hing, Cathy Holt, Debbie Rolfe, Enrica Papi, Freija Ter Heegde, Jingsong Wang, John Garcia, Mark Elliott, Mary Sheppard, Natasha Kapella, Richard Rendle, Shafaq Sikandar, Sherif Hosny, Soraia Silva, Soraya Koushesh, Susanna Cooper and Thomas Barrick. No writing assistance was used.

Results {#s3}
=======

Search strategy {#s3-1}
---------------

The results of the search strategy are presented in [figure 1](#F1){ref-type="fig"}. In total, 11 010 citations were identified. Of these, 141 papers were deemed potentially eligible and screened at full-text level. Of these, 82 met the selected criteria and were included.[@R17]

![Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow chart.](bmjopen-2020-038720f01){#F1}

Characteristics of included studies {#s3-2}
-----------------------------------

A summary of the included studies is presented as [table 1](#T1){ref-type="table"}. This consisted of 31 non-RCTs (27 observational cohort studies/four case-control studies) and 51 RCTs.

###### 

Characteristics of included studies

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                               Study design           Number joints (hip/knees)             Gender\         Country origin                                            Mean age (years)   Follow-up duration (months)   Pain outcome measures                                        Functional outcome measures
                                                                                                                            (male:female)                                                                                                                                                                           
  ------------------------------------------------------------ ---------------------- ------------------------------------- --------------- --------------------------------------------------------- ------------------ ----------------------------- ------------------------------------------------------------ -------------------------------------------------------------------------------------
  Ahedi *et al* [@R54]                                         Observational cohort   198 hips                              111:87          Australia                                                 UTD                132                           WOMAC Pain                                                   NA

  Akelman *et al* [@R20]                                       RCT                    107 knee                              UTD             USA                                                       23.5               84                            KOOS pain; SF-36 Body pain                                   SF-36 Physical; AP laxity; IKDC2000

  Amin *et al* [@R55]                                          Observational cohort   265 knees                             152:113         USA                                                       67                 30                            VAS Pain                                                     WOMAC Function

  Antony *et al* [@R56]                                        Observational cohort   463 knees                             245:218         USA                                                       63                 24                            WOMAC Pain                                                   NA

  Arden *et al* [@R57]                                         RCT                    474 knees                             185:289         UK                                                        64                 36                            WOMAC Pain                                                   WOMAC Function

  Ayral *et al* [@R58]                                         RCT                    665 knees                             259:406         Australia, Belgium, Canada,\                              61.3               12                            WOMAC Pain                                                   WOMAC Function
                                                                                                                                            Denmark, Finland, France, Hungary, Norway, Spain,\                                                                                                                      
                                                                                                                                            UK, USA                                                                                                                                                                 

  Baselga Garcia-Escudero and Miguel Hernández Trillos[@R59]   Observational cohort   118 knees                             43:75           Spain                                                     59.1               24                            NRS; WOMAC Pain                                              WOMAC Function

  Bevers *et al* [@R60]                                        Observational cohort   125 knees                             57:68           The Netherlands                                           57                 24                            WOMAC Pain                                                   WOMAC Function

  Bingham *et al* [@R53]                                       RCT                    2483 knees                            735:1748        USA\                                                      UTD                24                            WOMAC Pain                                                   WOMAC Function
                                                                                                                                            Canada\                                                                                                                                                                 
                                                                                                                                            Austria\                                                                                                                                                                
                                                                                                                                            Czech Republic\                                                                                                                                                         
                                                                                                                                            France\                                                                                                                                                                 
                                                                                                                                            Germany\                                                                                                                                                                
                                                                                                                                            Hungary\                                                                                                                                                                
                                                                                                                                            Ireland\                                                                                                                                                                
                                                                                                                                            Italy\                                                                                                                                                                  
                                                                                                                                            The Netherlands\                                                                                                                                                        
                                                                                                                                            Poland\                                                                                                                                                                 
                                                                                                                                            Croatia                                                                                                                                                                 

  Birmingham *et al* [@R61]                                    Observational cohort   126 knees                             100:26          Canada                                                    47.5               24                            KOOS Pain                                                    KOOS Function; SF-36 Physical; LEFS

  Bisicchia *et al* [@R52]                                     RCT                    150 knees                             47:103          Italy                                                     UTD                12                            VAS Pain; SF-36                                              SF-36

  Brandt *et al* [@R62]                                        RCT                    431 knees                             0:431           USA                                                       54.9               30                            WOMAC Pain; VAS Pain                                         WOMAC Function

  Brown *et al* [@R51]                                         RCT                    690 knees                             270:420         USA                                                       UTD                32 weeks                      WOMAC Pain; NRS weekly pain                                  WOMAC Function; SF-36 Function

  Brown *et al* [@R50]                                         RCT                    621 hips                              237:384         USA                                                       UTD                32 weeks                      WOMAC Pain                                                   WOMAC Function

  Bruyere *et al* [@R63]                                       RCT                    319 knee                              0:319           Belgium                                                   64.0               36                            WOMAC Pain                                                   WOMAC Function

  Campbell *et al* [@R49]                                      RCT                    100 knees                             28:72           Australia                                                 UTD                120                           American Knee Society Score; WOMAC Pain                      American Knee Society Score (function); WOMAC Function

  Chandrasekaran *et al* [@R48]                                Case control           111 hips                              66:45           USA                                                       UTD                24                            Modified Harris Hip Score; Nonarthritic hip score; VAS Pin   Modified Harris Hip Score; Nonarthritic hip score; Hip Outcome Score; Sports & ADLs

  Chandrasekaran *et al* [@R47]                                Case control           186 hips                              96:90           USA                                                       UTD                24                            Modified Harris Hip Score; Nonarthritic hip score; VAS Pin   Modified Harris Hip Score; Nonarthritic hip score; Hip Outcome Score; Sports & ADLs

  Conrozier *et al* [@R64]                                     RCT                    205 knees                             88:117          France                                                    65                 26                            WOMAC Pain; NRS walking pain                                 WOMAC Function

  Davis *et al* [@R19]                                         Case control           3132 knees                            UTD             USA                                                       UTD                48                            WOMAC Pain; KOOS Pain                                        WOMAC Function

  Dougados *et al* [@R46]                                      RCT                    507 hips                              202:305         France                                                    UTD                36                            VAS Pain                                                     Lequesne Index

  Dowsey *et al* [@R65]                                        Observational cohort   478 knees                             147:331         Australia                                                 70.8               24                            IKSS Pain                                                    IKSS Function

  Eckstein *et al* [@R45]                                      RCT                    1412 knees                            611:801         Austria                                                   UTD                48                            WOMAC Pain                                                   NA

  Ettinger *et al* [@R44]                                      RCT                    439 knees                             131:308         USA                                                       UTD                18                            Pain intensity score                                         Physical Test

  Felson *et al* [@R66]                                        Observational cohort   3498 knees                            867:1206        USA                                                       61.2               30                            WOMAC Pain                                                   PASE

  Felson *et al* [@R67]                                        Observational cohort   330 knees                             111:2111        USA                                                       62.1               15                            NA                                                           Quadriceps strength (N)

  Filardo *et al* [@R43]                                       RCT                    183 knees                             112:71          Italy                                                     UTD                48                            KOOS Pain; IKDC                                              KOOS Function; Tegner; IKDC

  Glass *et al* [@R42]                                         Observational cohort   4648 knees                            918:1486        USA                                                       UTD                24                            WOMAC Pain; NRS Pain                                         WOMAC Function

  Guermazi *et al* [@R41]                                      Case control           493 knees                             185:308         USA                                                       UTD                60                            WOMAC Pain                                                   PASE

  Hamilton *et al* [@R68]                                      Observational cohort   805 knees                             416:289         UK                                                        66                 30                            WOMAC Pain                                                   WOMAC Function

  Hellio le Graverand *et al* [@R69]                           RCT                    1457 knees                            343:1114        USA\                                                      61.0               180                           Oxford Knee Score                                            Oxford Knee Score; American Knee Society Score; Tegner
                                                                                                                                            Canada\                                                                                                                                                                 
                                                                                                                                            Australia, Belgium, Czech Republic, Germany, Hungary,\                                                                                                                  
                                                                                                                                            Italy,\                                                                                                                                                                 
                                                                                                                                            Poland, Russian Federation, Slovakia, Spain, Argentina\                                                                                                                 
                                                                                                                                            Peru                                                                                                                                                                    

  Henriksen *et al* [@R40]                                     RCT                    157 knees                             28:129          Denmark                                                   UTD                24                            WOMAC Pain                                                   WOMAC Function

  Hill *et al* [@R5]                                           RCT                    202 knees                             102:100         Australia                                                 61                 12                            KOO Pain                                                     KOOS Function and kinematic assessment

  Hochberg *et al* [@R70]                                      RCT                    522 knees                             84:438          France\                                                   62.7               24                            WOMAC Pain                                                   WOMAC Function
                                                                                                                                            Germany\                                                                                                                                                                
                                                                                                                                            Poland\                                                                                                                                                                 
                                                                                                                                            Spain                                                                                                                                                                   

  Hoeksma *et al* [@R71]                                       RCT                    109 hips                              33:76           The Netherlands                                           72                 6                             WOMAC Pain; Huskisson's VAS; EQ-5D Pain                      WOMAC Function; EQ-5D Function

  Housman *et al* [@R39]                                       RCT                    391 knees                             130:261         USA\                                                      UTD                6                             SF-36 Body Pain; Harris Hip Score; VAS Pain                  SF-36 Function; Harris Hip Score; ROM
                                                                                                                                            Canada\                                                                                                                                                                 
                                                                                                                                            France\                                                                                                                                                                 
                                                                                                                                            UK\                                                                                                                                                                     
                                                                                                                                            Germany                                                                                                                                                                 

  Huang *et al* [@R72]                                         RCT                    264 knees                             39:93           Taiwan                                                    62                 6                             WOMAC Pain                                                   NA

  Huizinga *et al* [@R73]                                      Observational cohort   298 knees                             201:97          The Netherlands                                           51                 12                            VAS Pain                                                     Lequesne index; walking speed

  Jin *et al* [@R6]                                            RCT                    413 knees                             205:208         Australia                                                 63.2               24                            WOMAC Pain; VAS Pain                                         WOMAC Function

  Kahn *et al* [@R74]                                          Observational cohort   174 knees                             70:102          USA                                                       67.0               6                             WOMAC Pain                                                   WOMAC Function

  Karsdal *et al* [@R38]                                       RCT                    2207 knees                            773:1424        Denmark                                                   UTD                24                            WOMAC Pain                                                   WOMAC Function

  Katz *et al* [@R37]                                          RCT                    330 knees                             143:187         USA                                                       UTD                12                            KOO Pain                                                     WOMAC Function; SF-36 Function

  Kim *et al* [@R75]                                           RCT                    352 knees                             9:153           Republic of Korea                                         68.1               144                           WOMAC                                                        Knee Society Knee Score Function; ROM; UCLA Activity

  Kinds *et al* [@R18]                                         RCT                    565 knees                             UTD             The Netherlands                                           UTD                60                            WOMAC Pain                                                   WOMAC Function

  Kongtharvonskul *et al* [@R36]                               RCT                    148 knees                             25:123          Thailand                                                  UTD                6                             WOMAC Pain; VAS Pain                                         WOMAC Function

  Lequesne *et al* [@R76]                                      RCT                    163 hips                              102:61          France                                                    63.2               24                            VAS Pain                                                     Lequesne Index

  Lohmander *et al* [@R35]                                     RCT                    170 knees                             52:116          Bulgaria\                                                 UTD                12                            WOMAC Pain                                                   WOMAC Function
                                                                                                                                            Canada\                                                                                                                                                                 
                                                                                                                                            Croatia\                                                                                                                                                                
                                                                                                                                            Finland\                                                                                                                                                                
                                                                                                                                            Germany\                                                                                                                                                                
                                                                                                                                            Poland\                                                                                                                                                                 
                                                                                                                                            Serbia\                                                                                                                                                                 
                                                                                                                                            Africa\                                                                                                                                                                 
                                                                                                                                            Sweden\                                                                                                                                                                 
                                                                                                                                            USA                                                                                                                                                                     

  Maheu *et al* [@R8]                                          RCT                    345 hips                              159:186         France                                                    62.2               36                            WOMAC Pain; Global Hip Pain                                  Lequesne Index; WOMAC Function; Global handicap NRS

  Marsh *et al* [@R34]                                         RCT                    168 knees                             57:112          Canada                                                    UTD                24                            WOMAC                                                        WOMAC

  McAlindion *et al* [@R33]                                    RCT                    146 knees                             57:89           USA                                                       UTD                24                            WOMAC Pain                                                   WOMAC Function; Physical Test

  Messier *et al* [@R32]                                       RCT                    316 knees                             89:227          USA                                                       UTD                18                            WOMAC Pain                                                   WOMAC Function; Physical Test

  Messier *et al* [@R77]                                       RCT                    142 knees                             37:105          USA                                                       68.5               18                            WOMAC Pain                                                   WOMAC Function; Physical Test

  Messier *et al* [@R78]                                       RCT                    454 knees                             128:325         USA                                                       66                 18                            WOMAC Pain                                                   WOMAC Function; Physical Test; SF-36 Physical

  Michel *et al* [@R31]                                        RCT                    300 knees                             146:154         Switzerland                                               UTD                24                            WOMAC Pain                                                   WOMAC Function; Physical Test

  Muraki *et al* [@R79]                                        Observational cohort   1558 knees                            553:1005        Japan                                                     67.0               40                            WOMAC Pain                                                   WOMAC Function;

  Muraki *et al* [@R80]                                        Observational cohort   1525 knees                            546:979         Japan                                                     67.0               40                            WOMAC Pain                                                   WOMAC Function

  Pavelka *et al* [@R30]                                       RCT                    277 knees; 117 hips                   109:285         Czech Republic                                            58                 60                            NA                                                           Lequesne Index

  Pavelka *et al* [@R81]                                       RCT                    202 knees                             45:157          Czech Republic                                            UTD                36                            WOMAC Pain                                                   WOMAC Function; Lequesne Index

  Pham *et al* [@R29]                                          Observational cohort   301 knees                             97:204          France                                                    UTD                12                            VAS Pain                                                     Lequesne Index

  Podsiadlo *et al* [@R28]                                     Observational cohort   114 knees                             49:65           Australia                                                 UTD                72                            WOMAC Pain                                                   WOMAC Function

  Rat *et al* [@R82]                                           RCT                    300 knees                             118:182         France                                                    67                 6                             SF-36 Body Pain; OAKHQOL Pain; VAS Pain                      Lequense Index; SF-36 Physical; OAKHQOL Physical Activity

  Raynauld *et al* [@R27]                                      RCT                    123 knees                             44:79           Canada                                                    UTD                24                            WOMAC Pain                                                   WOMAC Function

  Reginster *et al* [@R26]                                     RCT                    212 knees                             50:162          Belgium                                                   UTD                36                            WOMAC Pain                                                   WOMAC Function

  Reginster *et al* [@R83]                                     RCT                    1371 knees                            425:946         Australia\                                                62.9               36                            WOMAC Pain; VAS Pain                                         WOMAC Function
                                                                                                                                            Austria\                                                                                                                                                                
                                                                                                                                            Belgium\                                                                                                                                                                
                                                                                                                                            Canada\                                                                                                                                                                 
                                                                                                                                            Czech Republic\                                                                                                                                                         
                                                                                                                                            Denmark\                                                                                                                                                                
                                                                                                                                            Estonia\                                                                                                                                                                
                                                                                                                                            France\                                                                                                                                                                 
                                                                                                                                            Germany\                                                                                                                                                                
                                                                                                                                            Italy\                                                                                                                                                                  
                                                                                                                                            Lithuania\                                                                                                                                                              
                                                                                                                                            The Netherlands\                                                                                                                                                        
                                                                                                                                            Poland\                                                                                                                                                                 
                                                                                                                                            Portugal\                                                                                                                                                               
                                                                                                                                            Romania\                                                                                                                                                                
                                                                                                                                            Russian Federation\                                                                                                                                                     
                                                                                                                                            Spain\                                                                                                                                                                  
                                                                                                                                            UK                                                                                                                                                                      

  Riddle and Jiranek[@R25]                                     Observational cohort   467 knees                             209:258         USA                                                       UTD                24                            KOOS Pain                                                    WOMAC Function

  Romagnoli *et al* [@R84]                                     Observational cohort   105 knees                             16:69           Italy                                                     67.7               66                            Knee Society Score Clinical; VAS Pain                        Knee Society Score Function; ROM

  Roman-Blas *et al* [@R24]                                    RCT                    158 knees                             26:132          Spain                                                     UTD                6                             WOMAC Pain; VAS Pain                                         WOMAC Function

  Rozendaal *et al* [@R31]                                     RCT                    222 hips                              68:154          The Netherlands                                           UTD                24                            WOMAC Pain; VAS Pain                                         WOMAC Function

  Sanchez-Ramirez *et al* [@R85]                               Observational cohort   186 knees                             59:127          Canada                                                    61                 24                            WOAMC Pain                                                   WOMAC Function; Physical Test

  Sawitzke *et al* [@R86]                                      RCT                    662 knees                             215:447         USA                                                       57                 24                            WOMAC Pain                                                   WOMAC Function

  Skou *et al* [@R87]                                          Observational cohort   1682 knees                            434:818         Denmark                                                   62.2               84                            WOMAC Pain                                                   PASE; Physical Test

  Sowers *et al* [@R88]                                        Observational cohort   724 knees                             0:363           USA                                                       56                 132                           NA                                                           WOMAC Function; Physical Test

  Spector *et al* [@R89]                                       RCT                    284 knees                             115:169         UK                                                        63.3               12                            WOMAC Pain                                                   WOMAC Function

  Sun *et al* [@R90]                                           RCT                    121 knees                             31:90           Taiwan                                                    63                 6                             WOMAC Pain; VAS Pain                                         WOMAC Function; Lequesne Index; Physical Test

  Urish *et al* [@R22]                                         RCT                    336 knees                             96:67           USA                                                       UTD                36                            WOMAC                                                        WOMAC

  Valdes *et al* [@R17]                                        Observational cohort   860 knees; 928 hips                   UTD             UK                                                        UTD                38                            WOMAC Pain                                                   NA

  Van der Esch *et al* [@R98]                                  Observational cohort   402 knees                             64:137          The Netherlands                                           61.2               24                            NRS Pain                                                     WOMAC Function; Physical Test

  Weng *et al* [@R91]                                          RCT                    264 knees                             26:106          Taiwan                                                    64                 12                            VAS Pain                                                     Lequesne Index; ROM; Physical Test

  White *et al* [@R92]                                         Observational cohort   2110 knees                            992:118         USA                                                       61.0               84                            VAS Pain                                                     WOMAC Function

  Witt *et al* [@R93]                                          RCT                    294 knees                             70:154          Germany                                                   64.0               12                            WOMAC Pain; SF-36 Body Pain; VAS Pain                        WOMAC Function; SF-36 Function

  Yu *et al* [@R21]                                            Observational cohort   204 knees                             74:130          Australia                                                 UTD                12                            KOOS Pain; VAS Pain                                          KOOS ADL; Physical Function

  Yusuf *et al* [@R94]                                         Observational cohort   74 knees; 31 hips; 11 hip and knees   19:98           The Netherlands                                           60                 72                            WOMAC Pain; SF-36 Body Pain; Pain on movement                WOMAC Function; SF-36 Function; Physical Test
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ADLs, activities of daily living; IKDC, International Knee Documentation Committee; KOOS, Knee Injury and Osteoarthritis Outcome Score; LEFS, Lower Extremity Functional Scale; NA, not applicable; NRS, Numerical Rating Scale; OAKHQOL, Osteoarthritis Knee and Hip quality of Life Questionnaire; PASE, Physical Activity Scale for the Elderly; RCT, randomised controlled trial; ROM, range of motion; SF-36, Short Form-36; UTD, unable to determine; VAS, Visual Analogue Scale; WOMAC, Western Ontario and Mcmaster Universities Osteoarthritis Index.

In total, 45 767 knees were included in the analysis. This consisted of 13 870 men and 23 497 women; 4 studies did not report the gender of their cohorts.[@R17] Thirty-six studies were undertaken in the USA; 30 were undertaken in Europe; 9 were conducted in Australasia and 7 in Asia. Mean age of the cohorts was 61.7 years (SD: 7.56); 36 studies did not report age.[@R17] Mean follow-up period was 35.4 months (SD: 33.6). The most common measures of pain were WOMAC pain (n=55; 50%) and Visual Analogue Scale (VAS) Pain (n=21; 19%). The most frequently used measures of function were WOMAC function (n=52; 44%), physical tests (n=16; 14%) and SF-36 (n=10; 9%).

Methodological quality assessment {#s3-3}
---------------------------------

The methodological quality of the evidence was moderate ([online supplementary file 2](#SP1){ref-type="supplementary-material"};. Based on the results of the D&B non-RCT tool (31 studies; [online supplementary file 2](#SP1){ref-type="supplementary-material"}), recurrent strengths of the evidence were clear description of the participants recruited (29 studies; 94%), the representative nature that participants were to the population (31 studies; 100%), and variability in data presented for the main outcomes (31 studies; 100%). Furthermore, the main outcome measures were deemed reliable and valid in all studies (31 studies; 100%) with 89% (27 studies; 87%) studies adopting appropriate statistical analyses for their datasets. Recurrent limitations were not clearly reporting the main findings (20 studies; 65%), issues regarding the representation of the cohort from the wider public (18 studies; 58%) and only 6 studies (19%) basing their sample sizes on an *a prior* power calculation.

The results from the D&B RCT checklist (51 studies; [online supplementary file 3](#SP1){ref-type="supplementary-material"}) similarly reported findings with strength of the evidence around clear reporting of the cohort characteristics (49 studies; 96%) and interventions (50 studies; 98%), adoption of reliable/valid outcome measures (51 studies; 100%) and reported high compliance to study processes (37 studies; 73%). Recurrent weaknesses included recruiting cohorts which may not have been reflective of the wider population (19 studies; 37%), in clinic settings which may not have represented typical clinical practice (21 studies; 41%) and poorly adjusting for potential confounders in analyses (26 studies; 51%).

Knee OA {#s3-4}
-------

### Narrative review {#s3-4-1}

Findings from the narrative analysis found the following were predictors for worsening joint pain: KL3 or 4 in women (OR: 11.3; 95% CI 6.2 to 20.4), a WORMS lateral meniscal cyst (MC) score of 1 (OR: 4.3; 95% CI 1.2 to 15.4), presence of chronic widespread pain (CWP; OR: 3.2; 95% CI 1.9 to 5.3), increase of ≥2 in WORMS BML score after 15 months (OR: 3.2; 95% CI 1.5 to 6.8), meniscal maceration (OR: 2.8; 95% CI 1.8 to 4.4) or damage ≥2 in WORMS (OR: 1.8; 95% CI 0.9 to 3.6). We also found that the following were the highest predictors of worsening function in people with knee OA: KL of \<3 (OR: 3.3; 95% CI 0.7 to 15.9), modified KL 3a (OR: 1.7; 95% CI 0.7 to 3.8), modified KL 4a (OR: 1.5; 95% CI 0.7 to 3.0), presence of osteophytes (OR: 1.3; 95% CI 0.7 to 2.4), female gender (OR: 1.8 (95% CI 1.1 to 3.0) to OR: 2.1 (95% CI 1.2 to 3.5)), ethnicity (OR: 1.03; 95% CI 0.59 to 1.83) and synovitis ≥1 (OR: 1.3; 95% CI 0.8 to 1.9).

### Meta-analysis {#s3-4-2}

Two studies were identified where data could be evaluated for OA risk factors by meta-analysis.[@R41] Three variables significantly associated with the development of knee OA. As illustrated in [table 2](#T2){ref-type="table"} and [figure 2A--D](#F2){ref-type="fig"}, age (MD: 1.46, 95% CI 0.26 to 2.66; p=0.02; n=823), KL of ≥2 (MD: 2.04, 95% CI 1.48 to 2.81; p\<0.01; n=823) and knee effusion score ≥1 (OR: 1.35, 95% CI 0.99 to 1.83; p=0.05; n=823) were all associated with the development of knee OA based on moderate quality evidence. The variables of gender and BMI were not shown to be significantly associated with the knee OA development ([table 2](#T2){ref-type="table"}).

###### 

Meta-analysis results: exhibit knee osteoarthritis

  Variable                 N     Effect estimate         P value   Statistical heterogeneity (I^2^ %)   GRADE assessment
  ------------------------ ----- ----------------------- --------- ------------------------------------ ----------------------------
  Gender                   823   0.91 (0.48 to 1.72)\*   0.78      87                                   Low-quality evidence†
  Age                      823   1.46 (0.26 to 2.66)     0.02      0                                    Moderate-quality evidence‡
  KL ≥2                    823   2.04 (1.48 to 2.81)     \<0.01    35                                   Moderate-quality evidence‡
  Knee effusion score ≥1   823   1.35 (0.99 to 1.83)     0.05      0                                    Moderate-quality evidence‡
  BMI                      823   −0.08 (−0.75 to 0.58)   0.81      0                                    Moderate-quality evidence‡

\*Random effects model analysis.

†GRADE---outcomes downgraded one level due to risk of bias, two level due to imprecision and inconsistency.

‡GRADE---outcomes downgraded one level due to risk of bias.

BMI, body mass index; I2, inconsistency squared; KL, Kellgren Lawrence Scale; N, number of participants in analysis; NE, not estimable.

![(A) Forest plot to present the association between gender and presentation of knee osteoarthritis (OA). (B) Forest plot to present the association between age and presentation of knee OA. (C) Forest plot to present the association between knee effusion score greater or equal to 1 and presentation of knee OA. (D) Forest plot to present the association between body mass index and presentation of knee OA.](bmjopen-2020-038720f02){#F2}

Due to the limited availability of data, it was not possible to conduct the planned subgroup analyses to determine whether there was a difference in risk factors based on anatomical or geographical regions.

Hip OA {#s3-5}
------

### Narrative analysis {#s3-5-1}

This was based on low-quality evidence. There was no association between the development of hip BML and BMI or age. Predictors for worsening joint pain for people with hip OA included a large acetabular BML (OR: 5.2; 95% CI 1.2 to 22.9), a large femoral head BML (OR: 4.4; 95% CI 1.4 to 19.7) with any large hip BML (OR: 4.4; 95% CI 1.5 to 13.2), CWP (OR: 5.0; 95% CI 2.8 to 9.1) and depression (OR: 1.9; 95% CI 1.2 to 2.9). Baseline knee pain score (MD:−1.4; 95% CI −1.6 to −1.2) and baseline hip pain score (MD:−0.7; 95% CI −1.0 to −0.5) were significantly associated with the development of hip BMLs and pain.

### Meta-analysis {#s3-5-2}

There were insufficient data to permit meta-analysis for the hip OA dataset.

Discussion {#s4}
==========

Our systematic review and meta-analysis identified risk factors for knee and hip OA pain and structural damage based on evaluation of 82 studies. For the knee, increasing pain in knee OA was associated with KL grade 3 or 4 in women, WORMS lateral MC, presence of CWP, increase of ≥2 in WORMS BML score after 15 months and meniscal maceration. In addition, KL \<3, KL 3a, KL 4a, osteophyte presence and female gender were associated with worsening function in people with knee OA. On meta-analysis, age, radiological features (KL score of 2 or more) and knee effusion were associated with development and/or progression of knee OA.

Our meta-analysis identified risk factors that are appreciated only when results were pooled together. These were namely WORMS-defined knee effusion score ≥1. To our knowledge, this is currently the largest and most up to date systematic review of its kind, reviewing 82 primary studies in 41 810 participants. Nonetheless, some risk factors from our meta-analysis have been recognised previously. For example, Silverwood *et al* reported previous injuries are associated to developing knee OA, supporting the present analysis.[@R95] Kingsbury *et al* identified age and KL grade as predictive factors for developing knee OA, supporting the present findings.[@R96] The meta-analyses provided both novel and supporting findings for risk factors associated with developing and progressing knee OA. A machine learning study assessed risk factors associated with pain and radiological progression in knee OA found that BMLs, osteophytes, medial meniscal extrusion, female gender and urine CTX-II contributed to progression.[@R97] Nelson *et al's* work is supported by other studies.[@R95] Therefore, the findings of our analysis support previous findings.

After plain radiography, MRI was the most used modality with WORMS as the most common scoring reported for MRI. The MRI Osteoarthritis Knee Score (MOAKS),[@R99] expanded on WORMS by scoring entire subregions for BMLs rather than each BML, further division of cartilage regions and refined the features assessed in meniscal morphology. Due to this progression from WORMS, having no MOAKS studies included in our final selection was surprising. This could be due to the eligibility criteria being too restrictive. A future systematic review and meta-analysis focusing on the imaging aspect of evaluating OA will be important. In hip OA, the evaluation of BML size and location is essential in predicting pain progression and these can be assessed effectively using MRI. We recommend that all MRI studies for hip OA evaluate BML size and location.

Gait analysis is considered a risk factor for pain/function and was therefore included as a target outcome measure. However, few studies included gait analysis measures, which could not be included in the analysis, perhaps due to the minimum sample size (n=100) being too restrictive.

There were several limitations within our study. First, despite identifying novel risk factors for exhibiting knee OA, a small dataset was pooled together for the meta-analysis (two studies) compared with Silverwood *et al* (34 studies).[@R93] This was particularly apparent for hip OA where only 12 studies assessed this population.[@R8] Consequently, the small dataset influenced the GRADE assessment that determined the evidence as low to moderate, restricting the strength of the associations of risk factors with OA development and progression. Further work may impact our confidence in the estimated effect, for both studies recruiting participants with hip and knee OA. Second, the eligibility criteria may have been too restrictive, resulting in limited papers including gait analysis or MOAKS. Wet biomarkers were not included in our analyses. Finally, the inability to pool data was partly attributed to variability in methods to report data. Standardising data collection and reporting are important in conducting meta-analyses. We believe the following should be undertaken to improve data pooling in future work: ensuring group comparisons in studies are selected from the same population (people with confirmed OA) to improve internal validity, observational studies should conduct a power analysis to determine sample sizes and all studies should include absolute frequency of events data rather than summary ORs. Such considerations will improve future meta-analyses to identify OA risk factors.

To conclude, our work helps to develop steps towards building a stratification tool for risk factors for knee OA pain and structural damage development. We also highlight the need for collection of core datasets based on defined domains, which has recently also been highlighted by the OMERACT-OARSI core domain set for knee and hip OA.[@R13] Collection of future datasets based on standardised core outcomes will assist in more robust identification of risk factors for large joint OA.
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